Skip to main navigation Skip to search Skip to main content

Novel FAP-Targeted Heptamethine Cyanines for NIRF Imaging Applications

  • Rebecca Rizzo
  • , Martina Capozza
  • , Laura Conti
  • , LIDIA AVALLE
  • , Valeria Poli
  • , Enzo Terreno

Research output: Contribution to journalArticlepeer-review

Abstract

Fibroblast activation protein (FAP) is a pan-cancer target that is useful for imaging, ideally all epithelial cancers. This work aimed to develop, characterize, and validate two novel FAP-targeted probes for optical imaging, both in vitro and in vivo. IRDye800CW and FNIRTag heptamethine cyanines were conjugated to the NH precursor of the well-known FAP inhibitor FAPI-46, which is widely employed in nuclear medicine. In addition to synthesis, the dyes were characterized in terms of physicochemical properties, biodistribution, and imaging performances in a breast cancer tumor model. FAPI-FNIRTag showed a stronger fluorescence and higher photostability compared to FAPI-IRDye800CW. Notably, both compounds exhibited strong tumor accumulation in TUBO breast cancer-bearing mice 24 h postadministration, suggesting potential for further investigation as fluorescence-guided surgery (FGS) agents.
Original languageEnglish
Pages (from-to)1518-1528
Number of pages11
JournalMolecular Pharmaceutics
Volume22
Issue number3
DOIs
Publication statusPublished - 2025

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • FAP
  • breast cancer
  • heptamethine cyanines
  • near-infrared fluorescence imaging
  • optical imaging

Fingerprint

Dive into the research topics of 'Novel FAP-Targeted Heptamethine Cyanines for NIRF Imaging Applications'. Together they form a unique fingerprint.

Cite this